Want to see HK:0399 full AI Analyst Report?
Innovative Pharmaceutical Biotech (0399) Ratios
Innovative Pharmaceutical Biotech Ratios
HK:0399's free cash flow for Q2 2025 was $10.45M. For the 2025 fiscal year, HK:0399's free cash flow was increased by $0.00 and operating cash flow was $10.45M. See a summary of the company’s cash flow.
| Ratios | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.01 | 0.03 | 0.01 | 0.19 | 0.04 |
| Quick Ratio | 0.01 | 0.03 | 0.01 | 0.19 | 0.04 |
| Cash Ratio | 0.00 | 0.01 | 0.00 | 0.04 | 0.01 |
| Solvency Ratio | -0.31 | 0.10 | -0.20 | 0.30 | -0.38 |
| Operating Cash Flow Ratio | -0.01 | -0.02 | -0.02 | -0.12 | -0.03 |
| Short-Term Operating Cash Flow Coverage | -0.01 | -0.02 | -0.02 | -0.31 | -0.03 |
| Net Current Asset Value | $ -1.05B | $ -1.05B | $ -1.23B | $ -980.78M | $ -1.02B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.92 | 0.73 | 0.86 | 0.68 | 0.71 |
| Debt-to-Equity Ratio | -1.47 | -1.65 | -1.50 | -1.71 | -1.67 |
| Debt-to-Capital Ratio | 3.11 | 2.54 | 3.01 | 2.40 | 2.50 |
| Long-Term Debt-to-Capital Ratio | -0.15 | 11.11 | -0.14 | 2.57 | -0.69 |
| Financial Leverage Ratio | -1.59 | -2.26 | -1.74 | -2.54 | -2.36 |
| Debt Service Coverage Ratio | -0.26 | 0.57 | -0.01 | 2.12 | -0.22 |
| Interest Coverage Ratio | -0.05 | -0.06 | -0.09 | -0.13 | -0.11 |
| Debt to Market Cap | 3.34 | 3.18 | 3.91 | 4.30 | 2.72 |
| Interest Debt Per Share | 0.73 | 0.80 | 0.97 | 0.77 | 0.81 |
| Net Debt to EBITDA | -3.22 | 3.16 | -63.20 | 4.10 | -52.22 |
| Profitability Margins | |||||
| Gross Profit Margin | 8.99% | 12.74% | 10.63% | 9.46% | 9.25% |
| EBIT Margin | -14837.25% | 4805.16% | -256.37% | 2031.24% | -139.07% |
| EBITDA Margin | -14837.25% | 4819.43% | -233.08% | 2050.35% | -123.87% |
| Operating Profit Margin | -634.29% | -203.76% | -256.37% | -218.51% | -140.51% |
| Pretax Profit Margin | -27276.23% | 1497.15% | -3153.82% | 326.88% | -1396.77% |
| Net Profit Margin | -16544.09% | 1568.38% | -3042.70% | 2660.73% | -2605.52% |
| Continuous Operations Profit Margin | -27276.23% | 1497.15% | -3153.82% | 326.88% | -1396.77% |
| Net Income Per EBT | 60.65% | 104.76% | 96.48% | 813.97% | 186.54% |
| EBT Per EBIT | 4300.28% | -734.76% | 1230.18% | -149.60% | 994.07% |
| Return on Assets (ROA) | -31.88% | 7.48% | -17.75% | 21.26% | -28.20% |
| Return on Equity (ROE) | 50.78% | -16.91% | 30.90% | -53.98% | 66.47% |
| Return on Capital Employed (ROCE) | -11.73% | -1.36% | -8.73% | -1.88% | -3.54% |
| Return on Invested Capital (ROIC) | -1.29% | -1.01% | -1.56% | -1.82% | -1.58% |
| Return on Tangible Assets | -3891.74% | 1055.24% | -2269.94% | 1362.02% | -1319.79% |
| Earnings Yield | -115.01% | 32.56% | -80.68% | 135.92% | -108.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.58 | 1.29 | 1.26 | 1.17 | 0.98 |
| Payables Turnover | 13.69 | 3.10 | 1.79 | 1.24 | 2.52 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 8.58 | 3.95 | 12.81 |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Working Capital Turnover Ratio | -0.00 | -0.01 | -0.01 | -0.03 | -0.04 |
| Cash Conversion Cycle | 598.43 | 165.72 | 86.37 | 16.36 | 226.48 |
| Days of Sales Outstanding | 625.09 | 283.29 | 289.79 | 311.26 | 371.56 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 26.66 | 117.56 | 203.41 | 294.90 | 145.08 |
| Operating Cycle | 625.09 | 283.29 | 289.79 | 311.26 | 371.56 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 |
| Operating Cash Flow to Sales Ratio | -5.05 | -1.26 | -2.18 | -1.11 | -1.65 |
| Free Cash Flow Yield | -3.51% | -2.61% | -5.79% | -5.65% | -6.86% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.87 | 3.07 | -1.24 | 0.74 | -0.92 |
| Price-to-Sales (P/S) Ratio | 143.85 | 48.18 | 37.72 | 19.58 | 24.00 |
| Price-to-Book (P/B) Ratio | -0.44 | -0.52 | -0.38 | -0.40 | -0.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -28.50 | -38.36 | -17.26 | -17.69 | -14.58 |
| Price-to-Operating Cash Flow Ratio | -28.50 | -38.36 | -17.26 | -17.69 | -14.58 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.02 | 0.01 | -0.00 | 0.26 |
| Enterprise Value Multiple | -4.19 | 4.16 | -79.38 | 5.06 | -71.60 |
| Enterprise Value | 1.30B | 1.32B | 1.49B | 1.16B | 1.35B |
| EV to EBITDA | -4.19 | 4.16 | -79.38 | 5.06 | -71.60 |
| EV to Sales | 621.98 | 200.67 | 185.01 | 103.72 | 88.69 |
| EV to Free Cash Flow | -123.22 | -159.80 | -84.69 | -93.71 | -53.87 |
| EV to Operating Cash Flow | -123.22 | -159.80 | -84.69 | -93.71 | -53.87 |
| Tangible Book Value Per Share | -0.61 | -0.69 | -0.84 | -0.67 | -0.69 |
| Shareholders’ Equity Per Share | -0.39 | -0.40 | -0.54 | -0.38 | -0.41 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -7.14 | -0.87 |
| Revenue Per Share | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Net Income Per Share | -0.20 | 0.07 | -0.17 | 0.20 | -0.27 |
| Tax Burden | 0.61 | 1.05 | 0.96 | 8.14 | 1.87 |
| Interest Burden | 1.84 | 0.31 | 12.30 | 0.16 | 10.04 |
| Research & Development to Revenue | 1.00 | 0.22 | 0.59 | 0.74 | 0.40 |
| SG&A to Revenue | 5.43 | 1.96 | 2.11 | 1.55 | 1.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.02 | -0.08 | 0.07 | -0.34 | 0.12 |
Currency in HKD
